AU2001285232A1 - Alpha-difluoromethylornithine (dfmo) use in the human prostate - Google Patents
Alpha-difluoromethylornithine (dfmo) use in the human prostateInfo
- Publication number
- AU2001285232A1 AU2001285232A1 AU2001285232A AU8523201A AU2001285232A1 AU 2001285232 A1 AU2001285232 A1 AU 2001285232A1 AU 2001285232 A AU2001285232 A AU 2001285232A AU 8523201 A AU8523201 A AU 8523201A AU 2001285232 A1 AU2001285232 A1 AU 2001285232A1
- Authority
- AU
- Australia
- Prior art keywords
- dfmo
- difluoromethylornithine
- alpha
- human prostate
- prostate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VLCYCQAOQCDTCN-UHFFFAOYSA-N eflornithine Chemical compound NCCCC(N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-UHFFFAOYSA-N 0.000 title 1
- 210000002307 prostate Anatomy 0.000 title 1
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G11—INFORMATION STORAGE
- G11B—INFORMATION STORAGE BASED ON RELATIVE MOVEMENT BETWEEN RECORD CARRIER AND TRANSDUCER
- G11B7/00—Recording or reproducing by optical means, e.g. recording using a thermal beam of optical radiation by modifying optical properties or the physical structure, reproducing using an optical beam at lower power by sensing optical properties; Record carriers therefor
- G11B7/12—Heads, e.g. forming of the optical beam spot or modulation of the optical beam
- G11B7/22—Apparatus or processes for the manufacture of optical heads, e.g. assembly
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Optics & Photonics (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Optical Head (AREA)
- Moving Of The Head For Recording And Reproducing By Optical Means (AREA)
- Optical Recording Or Reproduction (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22771400P | 2000-08-24 | 2000-08-24 | |
US60/227,714 | 2000-08-24 | ||
PCT/US2001/026332 WO2002015895A2 (en) | 2000-08-24 | 2001-08-23 | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001285232A1 true AU2001285232A1 (en) | 2002-03-04 |
Family
ID=22854168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001285232A Abandoned AU2001285232A1 (en) | 2000-08-24 | 2001-08-23 | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
Country Status (5)
Country | Link |
---|---|
US (3) | US20020137797A1 (en) |
EP (1) | EP1351675A2 (en) |
JP (1) | JP2004506683A (en) |
AU (1) | AU2001285232A1 (en) |
WO (1) | WO2002015895A2 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004506683A (en) * | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α-Difluoromethylornithine (DFMO) suppresses polyamine levels in human prostate |
AU2002343609B2 (en) * | 2001-11-16 | 2008-12-11 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
RU2005130636A (en) * | 2003-03-04 | 2006-05-10 | Уайт (Us) | COMPOSITIONS AND METHODS FOR DIAGNOSTIC AND TREATMENT OF ASTHMA OR OTHER ALLERGIC OR INFLAMMATORY DISEASES |
CA2503554A1 (en) * | 2004-04-27 | 2005-10-27 | Proethic Laboratories, Llc | Dietary supplement |
WO2007075673A1 (en) * | 2005-12-20 | 2007-07-05 | University Of Hawaii | Treatment regimen for n-myc, c-myc, and l-myc amplified and overexpressed tumors |
BRPI0711280A2 (en) * | 2006-05-03 | 2012-03-06 | Wisconsin Alumni Research Foundation | METHODS OF REPRODUCING THE CONCENTRATION OF REACTIVE OXYGEN SPECIES IN THE PROSTATE OF A HUMAN HUMAN BEING, PROPHILICALLY TREATING A PROSTATE HUMAN HUMAN HUMAN CANCER POLYAMINE OXIDASE IN THE PROSTATE OF A HUMAN HUMAN BEING, DETERMINING OXIDATIVE STRESS IN HUMAN TISSUE, TREATING CANCER PROSTATE, REPRODUCING THE CONCENTRATION OF OXYGEN DEXYENE AND KIN DEXTENE SPECIES OXIDATIVE FABRIC STRESS OF MALE HUMAN PROSTATE, ORAL PHARMACEUTICAL COMPOSITION, KIT AND REAGENTS TO MEASURE CONCENTRATION OF EX VIVO OR IN VIVO REACTIVE OXYGEN SPECIES, ORGAN OR ORGAN CELL |
US9063122B2 (en) * | 2008-10-17 | 2015-06-23 | Alfredo Gallegos | Biomodulators for treatment or prevention of disease |
EP2430452B1 (en) | 2009-05-14 | 2014-06-25 | Arizona Board of Regents on Behalf of University of Arizona | Carcinoma diagnosis and treatments, based on odc1 genotype |
WO2011143579A2 (en) * | 2010-05-14 | 2011-11-17 | Arizona Board Of Regents On Behalf Of University Of Arizona | Cancer prevention and treatment methods based on dietary polyamine content |
FR2980709B1 (en) | 2011-09-29 | 2013-10-25 | Nutrialys Medical Nutrition Sa | COMPOSITIONS CONTAINING SPERMINE AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
US20130178454A1 (en) * | 2011-11-17 | 2013-07-11 | Shalender Bhasin | Combination of testosterone and ornithine decarboxylase (odc) inhibitors |
FR2985427B1 (en) | 2012-01-10 | 2016-07-15 | Nutrialys Medical Nutrition Sa | COMPOSITIONS CONTAINING AGMATIN AND THEIR USES IN THE PREPARATION OF DRUGS OR NUTRACEUTICAL SUBSTANCES |
LT2912193T (en) | 2012-10-29 | 2018-12-27 | Arizona Board Of Regents On Behalf Of University Of Arizona | Predictive markers for polyamine inhibitor cancer therapies |
CA2952771A1 (en) | 2014-06-18 | 2015-12-23 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Carcinoma diagnosis and treatment based on odc1 genotype |
CA3003149C (en) | 2015-10-30 | 2023-10-31 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
WO2017136533A1 (en) * | 2016-02-03 | 2017-08-10 | The Trustees Of The University Of Pennsylvania | Methods for treating diagnosing, and monitoring treatment of mucopolysaccharidoses |
WO2020236562A1 (en) | 2019-05-17 | 2020-11-26 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
WO2023039245A1 (en) * | 2021-09-10 | 2023-03-16 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Biomarkers for nonalcoholic steatohepatitis and treatments thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4413141A (en) * | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
US5614557A (en) * | 1977-07-11 | 1997-03-25 | Marion Merrell Et Compagnie C/O Merrell Pharmaceuticals Inc. | Method of controlling tumor growth rate |
US4330559A (en) * | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
US4499072A (en) * | 1982-11-29 | 1985-02-12 | Merrell Dow Pharmaceuticals Inc. | Process for treating diseases with ODC inhibitors |
US4859452A (en) * | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
US4925835A (en) * | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
US5002879A (en) * | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
EP0648114B1 (en) * | 1992-07-08 | 1997-09-17 | DIANORM G. Maierhofer GmbH | Liposomes, method of preparing them and their use in the preparation of drugs |
IL120303A0 (en) * | 1996-03-27 | 1997-06-10 | Pfizer | Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer |
WO1998019667A1 (en) * | 1996-11-01 | 1998-05-14 | Ilex Oncology, Inc. | Sustained release formulation containing dfmo |
AU5526898A (en) * | 1996-12-13 | 1998-07-03 | Ilex Oncology, Inc. | Isomeric pharmaceutical formulation containing dfmo for the treatment of cancer |
WO1999011279A1 (en) * | 1997-09-04 | 1999-03-11 | Rexall Sundown, Inc. | Composition and method for the treatment of benign prostatic hyperplasia and prostatitis |
US6258845B1 (en) * | 1998-03-28 | 2001-07-10 | The Regents Of The University Of California | DFMO and sulindac combination in cancer chemoprevention |
KR100370187B1 (en) * | 1998-08-05 | 2003-03-17 | 삼성전자 주식회사 | Optical recording/reproducing apparatus, tilt adjusting method therefor, and recording control method therefor |
JP2004506683A (en) * | 2000-08-24 | 2004-03-04 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | α-Difluoromethylornithine (DFMO) suppresses polyamine levels in human prostate |
-
2001
- 2001-08-23 JP JP2002520816A patent/JP2004506683A/en not_active Withdrawn
- 2001-08-23 WO PCT/US2001/026332 patent/WO2002015895A2/en not_active Application Discontinuation
- 2001-08-23 EP EP01964370A patent/EP1351675A2/en not_active Withdrawn
- 2001-08-23 AU AU2001285232A patent/AU2001285232A1/en not_active Abandoned
- 2001-08-24 US US09/938,846 patent/US20020137797A1/en active Pending
-
2004
- 2004-02-17 US US10/780,921 patent/US20040162353A1/en not_active Abandoned
- 2004-02-17 US US10/780,920 patent/US6831286B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20040160876A1 (en) | 2004-08-19 |
EP1351675A2 (en) | 2003-10-15 |
US20020137797A1 (en) | 2002-09-26 |
JP2004506683A (en) | 2004-03-04 |
US20040162353A1 (en) | 2004-08-19 |
US6831286B2 (en) | 2004-12-14 |
WO2002015895A3 (en) | 2003-07-31 |
WO2002015895A2 (en) | 2002-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001256184A1 (en) | 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases | |
AU2001287299A1 (en) | Benzoylpyrazols and their use as herbicides | |
AU2001285232A1 (en) | Alpha-difluoromethylornithine (dfmo) use in the human prostate | |
AU2002219135A1 (en) | Substituted 2-anilino-benzimidazoles and the use thereof as NHE-inhibitors | |
AU2001240637A1 (en) | Novel imidazotriazinones and the use thereof | |
AU8420301A (en) | Use | |
AU2001264258A1 (en) | Nonwoven-fabric laminate and use thereof | |
GB0101035D0 (en) | Formulation and use thereof | |
GB0025788D0 (en) | Use | |
AU7458201A (en) | Laminate and use thereof | |
AU2001261750A1 (en) | Laminate and its use | |
AU2002225749A1 (en) | Powered periotome | |
AU2002227925A1 (en) | Human beta-defensin-3 | |
AU5464901A (en) | Dichloropyridyl- and dichloroisothiazolyl-thiocarboxamides and their use as microbicides | |
AU2001232332A1 (en) | Leptin-resistance ameliorating agents | |
AU2000231564A1 (en) | Phosphororganic compounds and the use thereof | |
AUPQ526100A0 (en) | Improvements in single use syringes | |
AU4432001A (en) | Trityl-type compounds and their use | |
AU2001241875A1 (en) | Human dynamin 40322 | |
AU2001252062A1 (en) | Steatosis-modulating factors and uses thereof | |
GB0005070D0 (en) | Use | |
AU2001257100A1 (en) | Nalpha, nomega-dialkyl aminomethylenephosphonic acids and use thereof | |
AU2002219846A1 (en) | Novel use | |
AU6286101A (en) | New use | |
AU2002230539A1 (en) | Alkylthio- and aryl(heteroyl)thio-substituted p-phenylenediamines, their manufacture and their use in rubber |